Optimizing BTK Inhibitor Treatment in CLL: Dose Reduction Impact | Kerry Rogers, MD | ASH 2023

Optimizing BTK Inhibitor Treatment in CLL: Dose Reduction Impact | Kerry Rogers, MD | ASH 2023
Lenalidomide Early Intervention in High-Risk CLL | Kerry Rogers, MD | ASH 2023
Second Generation CLL Treatment: Zanubrutinib + Sonrotoclax | Constantine Tam, MD, MBBS | ASH 2023
Optimizing CLL Treatment: BTK Resistance and Dual Therapy | Kerry Rogers, MD | ASH 2023
ALPINE Trial: Zanubrutinib vs Ibrutinib in Treating CLL | Constantine Tam, MD, MBBS | ASH 2023
Richter's Transformation & CAR T Therapy in CLL | Adam Kittai, MD | ASH 2023
ABBV-525 in CLL and Non-Hodgkin Lymphoma Patients | Meghan Thompson, MD | ASH 2023
Costs of Venetoclax-Obinutuzumab vs. BTKi in CLL | Scott Huntington, MD, MPH, MSc | ASH 2023